- |||||||||| Leukine (sargramostim) / Partner Therap, IMA-901 / Immatics, sunitinib / Generic mfg.
Trial completion, IO biomarker, Metastases: IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - Aug 19, 2015 P3, N=330, Completed, Active, not recruiting --> Completed | Phase classification: PN/A --> P3 | Trial primary completion date: Nov 2016 --> Aug 2015 Active, not recruiting --> Completed
- |||||||||| Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment closed: Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma (clinicaltrials.gov) - Aug 13, 2015 P3, N=1660, Active, not recruiting, Initiation date: Jun 2015 --> Dec 2015 Recruiting --> Active, not recruiting
- |||||||||| Leukine (sargramostim) / Partner Therap
New P1 trial: Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent (clinicaltrials.gov) - Jun 12, 2015 P1, N=20, Recruiting,
- |||||||||| Leukine (sargramostim) / Partner Therap
Trial completion, Enrollment change: Sargramostim for Myeloid Dendritic Cell Deficiency (clinicaltrials.gov) - May 21, 2015 P1, N=2, Completed, Initiation date: Feb 2015 --> Jun 2015 Recruiting --> Completed | N=15 --> 2
- |||||||||| Intron A (interferon ?-2b) / Merck (MSD), Biogen, Leukine (sargramostim) / Partner Therap
Trial completion, Combination therapy, Metastases: Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) (clinicaltrials.gov) - Apr 20, 2015 P1, N=33, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Leukine (sargramostim) / Partner Therap
Trial completion date, Trial termination: GM-CSF in Patients With Pulmonary Alveolar Proteinosis (clinicaltrials.gov) - Apr 19, 2015 P2, N=48, Terminated, Active, not recruiting --> Completed Trial completion date: Sep 2004 --> Dec 2005 | Recruiting --> Terminated
- |||||||||| NeuVax (nelipepimut-S) / Dr. Reddy's
Enrollment closed, Trial primary completion date: PRESENT: Efficacy and Safety Study of NeuVax (clinicaltrials.gov) - Apr 15, 2015 P3, N=700, Active, not recruiting, Trial completion date: Sep 2004 --> Dec 2005 | Recruiting --> Terminated Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Apr 2018
- |||||||||| Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial primary completion date: Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - Apr 14, 2015 P1, N=42, Active, not recruiting, Trial primary completion date: Sep 2014 --> Sep 2015 Trial primary completion date: Sep 2014 --> Sep 2015
- |||||||||| Leukine (sargramostim) / Partner Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, IO biomarker, Metastases: Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors (clinicaltrials.gov) - Mar 25, 2015 P1, N=2, Terminated, Active, not recruiting --> Completed N=16 --> 2 | Recruiting --> Terminated; Funding ended
- |||||||||| Leukine (sargramostim) / Partner Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Trial primary completion date, IO biomarker, Metastases: Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 25, 2015 P1, N=5, Terminated, N=16 --> 2 | Recruiting --> Terminated; Funding ended N=24 --> 5 | Recruiting --> Terminated | Trial primary completion date: May 2015 --> Dec 2014; Funding ended
|